Roche has announced that the U.S. Food and Drug Administration has accepted its supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) for the treatment of Systemic Lupus Erythematosus (SLE). The regulatory decision is expected by December 2026.

The application is supported by results from the Phase III ALLEGORY study, which demonstrated statistically significant improvements in disease outcomes. The study showed that a higher proportion of patients receiving Gazyva in combination with standard therapy achieved meaningful reductions in disease activity compared to those on standard therapy alone.

Additional findings indicated improved remission rates, reduced disease flares and better control of symptoms among patients treated with the drug. The safety profile remained consistent with previous data, with no new concerns identified.

Gazyva is already approved for the treatment of lupus nephritis in the United States and European Union, as well as for certain types of blood cancers globally. The latest filing aims to expand its use to a broader population of lupus patients.

Systemic lupus erythematosus is a chronic autoimmune condition that can affect multiple organs, including the skin, joints, and kidneys, often leading to significant complications if not effectively managed. Current treatment options remain limited, highlighting the need for new targeted therapies.

The ALLEGORY study forms part of a broader clinical programme evaluating Gazyva across multiple immune-mediated diseases. Data from the study have also been submitted to European regulators for review.